/
Hot Topics

Hot Topics

image-20250108-100324.png

PHUSE collaborations are organised into a number of specialist Working Groups, each with a broad topic area. The Working Groups have specific projects designed to achieve a set of particular objectives. This page will highlight the latest news and information from our projects. Participation is open to anyone who wants to contribute and if you would like to get involved, please email workinggroups@phuse.global.

PHUSE collaborations are organised into a number of specialist Working Groups, each with a broad topic area. The Working Groups have specific projects designed to achieve a set of particular objectives. This page will highlight the latest news and information from our projects. Participation is open to anyone who wants to contribute and if you would like to get involved, please email workinggroups@phuse.global.

RWE Community Forum

RWE Community Forum

RWD for Regulatory Decision-Making: Learnings from Use Cases and Demonstration Projects

FDA guidance is clear that real world data (RWD) may be acceptable for regulatory approval when a randomised controlled trial is not feasible and the validity and trustworthiness of the real world study results are clearly demonstrated. To provide more operationalised guidance for meeting these standards, the presenters will share learnings from FDA use cases and ongoing demonstration projects. 

This Community Forum will be taking place virtually on 28 January at 14:00-15:00 (GMT) / 9:00-10:00 (EDT) / 15:00 (CET)

Data Transparency Winter Event 2025

Active since 2014, PHUSE’s Data Transparency Working Group has provided subject matter expertise for the review of draft deliverables and guidance documents from regulatory bodies (such as the EMA and Health Canada), as well as other industry organisations (such as TransCelerate) and academia. Since their inception in 2020, the free-to-attend Data Transparency Events have gone from strength to strength. These virtual events have created an unrestricted space where questions can be asked and challenges addressed. Individuals passionate about the area can come together to share vital knowledge, develop new ideas and spark innovation through presentations, panel discussions and Q&A sessions alongside experts in the data-sharing field.

The PHUSE Data Transparency Autumn Event will take place from 4–6 February 2025. Data Transparency Events offer you the chance to gain knowledge and experience from a wide data transparency community, allowing you to come together with experts from a variety of companies and backgrounds. During this virtual event, presentations will be delivered across the three days in bitesize chunks from 15:00-17:30 (GMT). There will also be a panel discussion and Q&A session focused on the day's themes. 

Real World Data Spring Event 2025

Real World Data Spring Event 2025

We're thrilled to announce a new Working Group event coming your way in 2025 – the PHUSE Real World Data Spring Event!

Taking place 9–10 April, this innovative event will bring the PHUSE Community together to explore the transformative potential of real world data (RWD).

Call for speakers is open, so wherever you are in the world, you can join us virtually – and for free – to share insights, learn and collaborate with like-minded individuals. Find out more about the event here. Look out for registration opening on 17 February!

Here’s your chance to take the virtual stage and share your expertise! We’re looking for speakers to inspire, inform and lead the conversation on RWD. To guide your submission, here are some focus areas that will be central to the event:

  • Data sources, lineage and provenance

  • Vendor-sponsor governance and alignment

  • Representing patient diversity

  • Overcoming challenges with unstructured data

Do you have a unique perspective that doesn’t fit into these categories? We encourage you to think outside the box and propose ideas that reflect the cutting edge of RWD.

Submit your 150-word abstract by 22 January. 

PHUSE/FDA CSS 2025

PHUSE/FDA CSS 2025

In its 14th year, the PHUSE/FDA Computational Science Symposium (CSS) will be expanding its global reach! In addition to Silver Spring, Maryland, we will be running a simultaneous event in Utrecht, the Netherlands!

Mark Your Calendars!

The US event will be in Silver Spring, Maryland 19-21 May, and the EU event will be in Utrecht, the Netherlands 20-21 May.

Please visit the PHUSE website for more information.

Registration is now open!

End to End RBQM Education – Make the most out of innovation and ensure it’s done right!

End to End RBQM Education – Make the most out of innovation and ensure it’s done right!

Join the webinar to learn why change is not only an idea but a necessity. We will explore where old habits need to be retired and where new initiatives have proven to increase efficiency and reduce cost without impacting on quality.

This Webinar will be taking place virtually on 20 February at 15:00-14:00 (GMT) / 8:00-9:00 (EST) / 14:00-15:00 (CET)

Working Group Quarterly Report

Working Group Quarterly Report

We have just published the last Working Group Report for 2024! You can view the Quarter 4 summary here, including the project reports and some of the highlights across our Working Groups for this final quarter. Don’t forget to check out the Working Group Events Report too, which provides a breakdown of the data collected from the Working Group Events for 2024.

Well done to all our Working Groups who have had a fantastic 2024!

Announcement - Emerging Trends and Technology Working Group Is Changing It's Name to Emerging Trends and Innovation

Announcement - Emerging Trends and Technology Working Group Is Changing It's Name to Emerging Trends and Innovation

The "Emerging Trends and Technology" (ET&T) Working Group is changing its name! This Working Group will now be called "Emerging Trends and Innovation" (ET&I). Hear from one of the Working Group's Leads, Mike Hamidi, on why they are making this change:

"The proposed name change from Emerging Trends & Technologies to Emerging Trends & Innovation reflects a broader focus beyond just technological enablement. This shift encompasses not only ongoing developments in areas such as AI/ML, digital health technologies, and healthcare standards but also aims to provide deeper insights into these and other evolving topics. We believe this adjustment will preserve the emphasis on emerging trends while enhancing our commitment to delivering valuable industry innovations."

The SEND Industry Feedback Survey project within the Nonclinical Topics Working Group have published their 2025 SEND survey! This is the 9th year the survey has taken place. The survey will be open from December to 29 January and the data collected will be anonymous. The results will be first available at the PHUSE Computational Science Symposium 2025 and will then be posted to the SEND Industry Feedback Survey site.

The Submitting Real World Data project within the Real World Evidence Working Group, has published a Blog. This Blog post explores possible approaches for submission of real world data to regulatory bodies. Real world data, as defined by the Food and Drug Administration in their guidance, comprises data collected from non-interventional study designs. (1) From project group discussions, ‘claims’ and ‘electronic health records’ comprise most real world data used in providing clinical evidence. Fast Health Interoperability Resources, or FHIR, is a platform used by HL7 for health information exchange. (2) This platform is widely used to exchange healthcare information, as far as claims and EHR data is concerned. As a result, a significant portion of real world data used by the pharma/biotech industry follows HL7-FHIR.

The AE Groupings in Safety (AEGiS) project within the Safety Analytics Working Group has published a new white paper. This white paper outlines why using standard AE groupings for queries is key to understanding a drug’s safety profile, discusses assumptions underlying the use of standard queries for estimation and outlines the benefits of standard queries when available. When standard queries are not available, but detailed analysis of a specific medical condition is needed, this document recommends a process to develop and maintain a custom query that can be replicated by regulatory authorities. 

The SDTM ADaM Implementation FAQ project within the Optimizing the Use of Data Standards Working Group has published a new FAQ! They have answered a FAQ with SDTM/ADaM IG Nuances, which is about the Use of Different Versions of MedDRA SMQs and CMQs for a Single Study. You can view this question and see the FAQ's this project has answered so far via here

Do you have a SDTM ADaM Implementation FAQ question? You can send your questions to the team by emailing workinggroups@phuse.global

The Estimands in Safety Analytics, a new project within the Safety Analytics Working Group, is now calling for volunteers. The value of well-defined safety estimands is not generally appreciated and has not been communicated well to safety scientists. 

  • Safety analyses are often ambiguous and, in some cases, carry the risk of being misinterpreted.

  • A better understanding and consequently a more consistent application of a robust estimand framework in the analysis of safety data would eliminate this ambiguity and drive clarity on both the specific question an analysis addresses, as well as the answer to that question.

If you would like to volunteer or learn more about this project, email workinggroups@phuse.global. Closing date: 14 February.

The Kick-Off Meeting for this project will be held on 18 February at 14:00-15:00 (GMT) / 9:00-10:00 (EST).

The Process for Aggregate Assessment of Clinical Trial AE Data, a new project within the Safety Analytics Working Group, is now calling for volunteers. The FDA’s 2021 draft update to the ‘Final Rule’ strongly supports aggregate assessment of clinical trial AE data, but provides little guidance on the best processes to use at different stages of development.

  • With a clear process that defines approaches to the differing challenges of AE assessment in early development compared with Phase III, the overall end-user experience for internal and external stakeholders would be improved.

  • When related preferred terms are grouped together, it would be beneficial to have a consistent process for analysis plan documentation, SDTM/ADaM specifications, and analysis displays.

 If you would like to volunteer or learn more about this project, email workinggroups@phuse.global. Closing date: 21 February.

The Kick-Off Meeting for this project will be held 25 February at 16:00-17:00 (GMT) / 11:00-12:00 (EST).

The Process for Aggregate Assessment of Clinical Trial AE Data, a new project within the Safety Analytics Working Group, is now calling for volunteers. The FDA’s 2021 draft update to the ‘Final Rule’ strongly supports aggregate assessment of clinical trial AE data, but provides little guidance on the best processes to use at different stages of development.

  • With a clear process that defines approaches to the differing challenges of AE assessment in early development compared with Phase III, the overall end-user experience for internal and external stakeholders would be improved.

  • When related preferred terms are grouped together, it would be beneficial to have a consistent process for analysis plan documentation, SDTM/ADaM specifications, and analysis displays.

 If you would like to volunteer or learn more about this project, email workinggroups@phuse.global. Closing date: 21 February.

The Kick-Off Meeting for this project will be held 25 February at 16:00-17:00 (GMT) / 11:00-12:00 (EST).

If you would like to get involved in a PHUSE Working Group Project, please explore the projects via the Working Group Tabs and contact the PHUSE Office on workinggroups@phuse.global to express your interest. 

Working Groups Report: Includes project updates, recent and upcoming deliverables and future plans for each Working Group.

Monthly Mailings: The monthly newsletter. Here you will find a full update from each month of the year, easily accessible and divided into key areas of PHUSE.

PHUSE Blogs: Fancy a quick read? A blog is a perfect way to catch up on all things Working Groups. Get the lowdown on the latest events from across the globe and stay updated on industry topics brought to you by industry professionals. 

Initiate and lead a new project under the PHUSE Working Groups umbrella. The new project must address problems of significant relevance to computational science related to drug, biological and device development and must meet all of the guidelines for projects within the collaboration, including the following mandatory requirements: 

  • The projects must address significant research issues relevant to Computational Science

  • The project must not attempt to address FDA policy issues

  • There must be at least one Project Lead personally involved in planning and carrying out the project

New projects can be submitted anytime during the year, click here to submit. 

Related pages